Olezarsen for Hypertriglyceridemia in Patients at High Cardiovascular Risk | New England Journal of Medicine https://t.co/IBN1J0JGkC
Congratulations to our own @BrianBergmark and the TIMI Study Group!!
Diabetes remains a major risk factor!
Published now in @CircAHA, we found a higher risk of adverse CV events in pts with DM and LM dz.
Moreover, compared with CABG, PCI resulted in no difference in the risk of death, but there were key differences for nonfatal events.
At #TCT2023, @PinakShahMD, @djc795, @hahn_rt, @PhilippLurz, and others discussed new data from the TRILUMINATE trial, which indicates that tricuspid TEER is safe and effective for patients with severe TR.
https://t.co/Cuu3HYfak1
Excited to share our new study now in @JAMACardio, highlighting outcomes in pts with left main disease and acute coronary syndrome after PCI vs CABG. Risk of 5-yr death similar, but tradeoffs for nonfatal events.
Huge thanks to @BrianBergmark and Dr. Sabatine! @TIMIStudyGroup